Rigosertib sodium, also known as ON-01910 sodium, is a small molecule drug that has shown promise in the treatment of various cancers, primarily myelodysplastic syndromes (MDS). Rigosertib sodium acts as a selective inhibitor of the enzyme Polo-like kinase 1 (PLK1), a protein that is highly expressed in many cancers and plays a critical role in cell division and growth. By targeting PLK1, rigosertib sodium works to inhibit the growth and proliferation of cancer cells.
Chemical name: sodium (E)-2-(2-methoxy-5-((2,4,6-trimethoxyphenyl)amino)phenyl)ethenyl sulfonate Molecular formula: C18H20N2Na2O9S Formula weight: 502.4 g/mol CAS No: 1225497-78-8
Top Ten Keywords from Google and Synonyms:
Synonyms: ON-01910, ON-01910.Na, sodium 2-(2-methoxy-5-((2,4,6-trimethoxyphenyl)amino)phenyl)ethenyl sulfonate
Health Benefits of Rigosertib Sodium: Rigosertib sodium has demonstrated significant promise in the treatment of myelodysplastic syndromes (MDS), a group of disorders that affect the production of blood cells and can progress to acute myeloid leukemia (AML). Clinical studies have shown that rigosertib sodium can improve overall survival and delay the progression of MDS to AML, making it an important treatment option for patients with this condition. Rigosertib sodium has also shown promise in the treatment of various other cancers, including solid tumors such as pancreatic and lung cancers.
Potential Effects: The primary effect of rigosertib sodium is the inhibition of the Polo-like kinase 1 (PLK1) enzyme, which plays a key role in cell division and growth. By targeting this protein, rigosertib sodium works to slow or stop the growth and proliferation of cancer cells. In addition to its potential benefits in the treatment of MDS and other cancers, rigosertib sodium has also shown potential in the treatment of neurofibromatosis type 2 (NF2), a genetic disorder that causes the growth of benign tumors in the nervous system.
Product Mechanism: Rigosertib sodium acts as a selective inhibitor of the enzyme Polo-like kinase 1 (PLK1), a protein that is highly expressed in many cancers and plays a critical role in cell division and growth. By binding to PLK1, rigosertib sodium disrupts its function and inhibits the growth and proliferation of cancer cells. This target is central to the cell cycle, and when disrupted, it causes cell cycle arrest and numerous changes in gene expression that can be lethal to cancer cells.
Safety: Like all medications, rigosertib sodium has potential side effects and safety concerns. While rigosertib sodium is generally well-tolerated, it can cause gastrointestinal issues such as nausea, vomiting, and diarrhea, as well as fatigue and weakness. Additionally, rigosertib sodium can cause anemia and neutropenia, which can increase the risk of infection. As with all cancer treatments, it is important to discuss any potential risks with your healthcare provider.
Dosing Information: The dosing of rigosertib sodium will depend on a variety of factors, including the type and stage of cancer being treated, as well as the patient's overall health and medical history. Rigosertib sodium is typically administered intravenously (IV) in a clinic or hospital setting, and the dose and frequency of dosing will be determined by your healthcare provider. It is important to follow your treatment plan carefully and to notify your healthcare provider of any side effects or concerns.
Conclusion: Rigosertib sodium is a targeted therapy that acts as a selective inhibitor of the Polo-like kinase 1 (PLK1) enzyme, which plays a critical role in cell division and growth. By inhibiting PLK1, rigosertib sodium works to slow or stop the growth and proliferation of cancer cells. This drug has shown significant promise in the treatment of myelodysplastic syndromes (MDS) and has also been studied for its potential use in the treatment of solid tumors and other hematopoietic malignancies. While rigosertib sodium has potential side effects and safety concerns, it is an important medication in the fight against cancer and can offer hope for patients with this disease.
